Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (1125)	5/19/2000 9:03:00 AM
From: david james	Read Replies (1) \| Respond to of 52153

BLOOM 5/19/00 - 8:48:50 AM ..... february that the effect from the asco conference could be "strong and swift." He says going back to 1990 typically biotechs in the aggregate have gained about 8.5% Leading up to and around the conference. But he says that gains for companies presenting at the conference have been much more dramatic. One sector becker says investors should pay close attention to is that do with monoclonal antibodies which includes such therapies as receptin from genentech. tveyes.com And from CBS.Marketwatch cbs.marketwatch.com Cancer conference to begin in New Orleans By Stephanie O'Brien, CBS MarketWatch Last Update: 9:51 PM ET May 18, 2000 NewsWatch NEW YORK (CBS.MW) -- Analysts and investors will be paying close attention to biotech stocks next week, as cancer specialists from around the world convene Saturday in New Orleans for the 36th Annual Meeting of the American Society of Clinical Oncology. Data on the latest advances in clinical cancer research will be presented at the conference, highlighting breakthroughs in breast, lung, kidney and stomach cancers.